The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites
Abstract
BACKGROUND: In vitro experiments suggest that circulating metabolites of oxycodone are opioid receptor agonists. Clinical and animal studies to date have failed to demonstrate a significant contribution of the O-demethylated metabolite oxymorphone toward the clinical effects of the parent drug, but the role of other putative circulating active metabolites in oxycodone pharmacodynamics remains to be examined. METHODS: Pharmacokinetics and pharmacodynamics of oxycodone were investigated in healthy human volunteers; measurements included the time course of plasma concentrations and urinary excretion of metabolites derived from N-demethylation, O-demethylation, and 6-keto-reduction, along with the time course of miosis and subjective opioid side effects. The contribution of circulating metabolites to oxycodone pharmacodynamics was analyzed by pharmacokinetic-pharmacodynamic modeling. The human study was complemented by in vitro measurements of opioid receptor binding and activation studies, as well as in vivo studies of the brain distribution of oxycodone and its metabolites in rats. RESULTS: Urinary metabolites derived from cytochrome P450 (CYP) 3A-mediated N-demethylation of oxycodone (noroxycodone, noroxymorphone, and alpha- and beta-noroxycodol) accounted for 45% +/- 21% of the dose, whereas CYP2D6-mediated O-demethylation (oxymorphone and alpha- and beta-oxymorphol) and 6-keto-reduction (alpha- and beta-oxycodol) accounted for 11% +/- 6% and 8% +/- 6% of the dose, respectively. Noroxycodone and noroxymorphone were the major metabolites in circulation with elimination half-lives longer than that of oxycodone, but their uptake into the rat brain was significantly lower compared with that of the parent drug. Pharmacokinetic-pharmacodynamic modeling indicated that the time course of pupil constriction is fully explained by the plasma concentration of the parent drug, oxycodone, alone. The metabolites do not contribute to the central effects, either because of their low potency or low abundance in circulation or as a result of their poor uptake into the brain. CONCLUSIONS: CYP3A-mediated N-demethylation is the principal metabolic pathway of oxycodone in humans. The central opioid effects of oxycodone are governed by the parent drug, with a negligible contribution from its circulating oxidative and reductive metabolites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cloning of a Delta Opioid Receptor by Functional Expression
Evans, C. J., Keith, D. E., Morrison, H., Magendzo, K., & Edwards, R. H. (1992) · Science · doi:10.1126/science.1335167 · Cited by 1,233
Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine
Sheiner, L. B., Stanski, D. R., Vozeh, S., Miller, R. D., & Ham, J. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1979253358 · Cited by 1,134
In silico prediction of blood–brain barrier permeation
Clark, D. E. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02827-7 · Cited by 483
SAAM II: Simulation, analysis, and modeling software for tracer and pharmacokinetic studies
Barrett, P. H. R., Bell, B. M., Cobelli, C., Golde, H., Schumitzky, A., Vicini, P., & Foster, D. M. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90064-6 · Cited by 445
Diversity of Mechanism-Based Pharmacodynamic Models
Mager, D. E., Wyska, E., & Jusko, W. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.510 · Cited by 345
Huang, P., Kehner, G. B., Cowan, A., & Liu-Chen, L.-Y. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29586-0 · Cited by 340
Self-citationAffinity, potency and efficacy of tramadol and its metabolites at the cloned human µ-opioid receptor
Gillen, C., Haurand, M., Kobelt, D. J., & Wnendt, S. (2000) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s002100000266 · Cited by 287
The intrinsic antinociceptive effects of oxycodone appear to be κ -opioid receptor mediated
Ross, F. B., & Smith, M. T. (1997) · Pain · doi:10.1016/s0304-3959(97)00093-6 · Cited by 259
Mu receptor binding of some commonly used opioids and their metabolites
Chen, Z. R., Irvine, R. J., Somogyi, A. A., & Bochner, F. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90150-a · Cited by 255
The Effect of Intrinsic Efficacy on Opioid Tolerance
Duttaroy, A., & Yoburn, B. C. (1995) · Anesthesiology · doi:10.1097/00000542-199505000-00018 · Cited by 214
Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication
Cascorbi, I. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.33.s2.3.x · Cited by 206
Molecular cloning and expression of a rat κ opioid receptor
Li, S., Zhu, J., Chen, C., Chen, Y. W., Deriel, J. K., Ashby, B., & Liu-Chen, L. Y. (1993) · Biochemical Journal · doi:10.1042/bj2950629 · Cited by 197
Self-citationPharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone*
Kaiko, R. F., Benziger, D. P., Fitzmartin, R. D., Burke, B. E., Reder, R. F., & Goldenheim, P. D. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90024-7 · Cited by 180
Leow, K. P., Smith, M. T., Williams, B., & Cramond, T. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.176 · Cited by 150
A review of oxycodone's clinical pharmacokinetics and pharmacodynamics
Pöyhiä, R., Vainio, A., & Kalso, E. A. (1993) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(93)90101-z · Cited by 146
Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy
Davis, M. P., Varga, J., Dickerson, D., Walsh, D., LeGrand, S. B., & Lagman, R. L. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-002-0385-9 · Cited by 121
Unadkat, J. D., Bartha, F. A., & Sheiner, L. B. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.143 · Cited by 116
Yoburn, B. C., Shah, S., Chan, K., Duttaroy, A., & Davis, T. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)00375-s · Cited by 99
Kalso, E. A., Vainio, A., Mattila, M. J., Rosenberg, P. H., & Seppαlä, T. (1990) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1990.tb00838.x · Cited by 95
Thompson, C. M., Wojno, H., Greiner, E., May, E. L., Rice, K. C., & Selley, D. E. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.058602 · Cited by 92
Pöyhiä, R., & Kalso, E. A. (1992) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1992.tb00441.x · Cited by 86
Kaplan, H. L., Busto, U. E., Baylon, G. J., Cheung, S. W., Otton, S. V., Somer, G. R., & Sellers, E. M. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36599-1 · Cited by 86
Blood-Brain Barrier Equilibration of Codeine in Rats Studied with Microdialysis
Xie, R., & Hammarlund‐Udenaes, M. (1998) · Pharmaceutical Research · doi:10.1023/a:1011929910782 · Cited by 71
Bitsios, P., Szabadi, E., & Bradshaw, C. M. (1999) · Psychopharmacology · doi:10.1007/s002130050949 · Cited by 71
Schmitt, J. A. J., Riedel, W. J., Vuurman, E. F. P. M., Kruizinga, M. J., & Ramaekers, J. G. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0993-y · Cited by 69
Influence of polarity on dose-response relationships of intrathecal opioids in rats
Plummer, J. L., Cmielewski, P., Reynolds, G. D., Gourlay, G. K., & Cherry, D. A. (1990) · Pain · doi:10.1016/0304-3959(90)91131-2 · Cited by 58
Safety and Efficacy of Controlled‐Release Oxycodone: A Systematic Literature Review
Rischitelli, D. G., & Karbowicz, S. H. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.11.898.33628 · Cited by 55
Leow, K. P., & Smith, M. T. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00849-3 · Cited by 54
Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity.
Caraco, Y., Tateishi, T., Guengerich, F. P., & Wood, A. J. J. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07426-4 · Cited by 52
Phillips, M. A., Bitsios, P., Szabadi, E., & Bradshaw, C. M. (2000) · Psychopharmacology · doi:10.1007/s002139900334 · Cited by 51
Webb, J. A., Rostami‐Hodjegan, A., Abdul‐Manap, R., Hofmann, U., Mikus, G., & Kamali, F. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01414.x · Cited by 47
Phimmasone, S., & Kharasch, E. D. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)23711-4 · Cited by 43
Self-citationMurphey, L. J., & Olsen, G. D. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22725-2 · Cited by 33
Cited by
Pergolizzi, J., Böger, R. H., Budd, K., Dahan, A., Erdine, S., Hans, G., Kress, H., Langford, R., Likar, R., Raffa, R. B., et al. (2008) · Pain Practice · doi:10.1111/j.1533-2500.2008.00204.x · Cited by 854
Smith, H. S. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60750-7 · Cited by 696
Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Klein, T. E., Caudle, K. E., Haidar, C. E., Shen, D. D., Callaghan, J. T., Sadhasivam, S., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.254 · Cited by 680
Self-citationFunctional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593
Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs
Volpe, D. A., Tobin, G. A. M., Mellon, R. D., Katki, A. G., Parker, R. J., Colatsky, T., Kropp, T. J., & Verbois, S. L. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.12.007 · Cited by 446
Metadata
- Authors
- LALOVIC, B., KHARASCH, E., HOFFER, C., RISLER, L., LIUCHEN, L., & SHEN, D.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2006-05
- Volume
- 79
- Issue
- 5
- Pages
- 461-479
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2141895799
- Cited by
- 413
- References
- 33
- FWCI
- 23.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.